These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6970943)

  • 1. [Hemodialysis dementia].
    Egídio J; Júnior R; Ianhez LE; Sabbaga E
    AMB Rev Assoc Med Bras; 1980 Aug; 26(8):261-3. PubMed ID: 6970943
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neurologic complications in hemodialysis patients].
    Goulon-Goeau C; Saïd G
    Rev Prat; 1990 Mar; 40(7):644-6. PubMed ID: 2326590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uremia and mechanisms of aluminium neurotoxicity: an overview.
    Savazzi GM
    Int J Artif Organs; 1991 Jan; 14(1):13-7. PubMed ID: 1674501
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurologic disorders in renal failure (second of two parts).
    Raskin NH; Fishman RA
    N Engl J Med; 1976 Jan; 294(4):204-10. PubMed ID: 172790
    [No Abstract]   [Full Text] [Related]  

  • 5. Progressive dialysis encephalopathy from dialysate aluminum.
    Rozas VV; Port FK; Rutt WM
    Arch Intern Med; 1978 Sep; 138(9):1375-7. PubMed ID: 686928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum and dialysis dementia.
    Mayor GH
    Ann Intern Med; 1979 Sep; 91(3):497-8. PubMed ID: 573084
    [No Abstract]   [Full Text] [Related]  

  • 7. [Water purification in dialysis treatment. Aluminum and encephalopathy].
    Hagstam KE; Lindergård B; Lindholm T; Thysell H
    Lakartidningen; 1980 Jun; 77(26-27):2425-7. PubMed ID: 7401791
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease.
    Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A
    Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long term CaCO3 treatment of chronic hemodialysis patients--an attempt to prevent and treat aluminum osteopathy].
    Matsubara M; Totsune K; Saito T; Yoshinaga K; Unagami H; Sato H
    Nihon Jinzo Gakkai Shi; 1988 Nov; 30(11):1349-54. PubMed ID: 3236516
    [No Abstract]   [Full Text] [Related]  

  • 10. Aluminum related dialysis osteomalacia and dementia after prolonged use of the Redy cartridge.
    Pierides AM; Frohnert PP
    Trans Am Soc Artif Intern Organs; 1981; 27():629-33. PubMed ID: 7331145
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical aspects of dialysis dementia.
    Silke B; Fitzgerald GR; Hanson S; Carmody M; O'Dwyer WF
    Ir Med J; 1978 Jan; 71(1):10-2. PubMed ID: 624610
    [No Abstract]   [Full Text] [Related]  

  • 12. Dialysis encephalopathy.
    Alfrey AC
    Kidney Int Suppl; 1986 Feb; 18():S53-7. PubMed ID: 3457997
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nervous system disorders induced by occupational exposure to aluminium compounds: a literature review].
    Sińczuk-Walczak H
    Med Pr; 2001; 52(6):479-81. PubMed ID: 11928679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate.
    O'Hare JA; Murnaghan DJ
    N Engl J Med; 1982 Mar; 306(11):654-6. PubMed ID: 7057824
    [No Abstract]   [Full Text] [Related]  

  • 15. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polyneuropathy and central nervous system diseases before and after heart transplantation. Is cyclosporin neurotoxic?].
    Porschke H; Strenge H; Stauch C
    Dtsch Med Wochenschr; 1991 Oct; 116(42):1577-82. PubMed ID: 1935623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 19. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum neurotoxicity: a reevaluation.
    Murray JC; Tanner CM; Sprague SM
    Clin Neuropharmacol; 1991 Apr; 14(2):179-85. PubMed ID: 2015614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.